Journal of Urology PSA Article

Journal of Urology PSA Article

A recent article from the Journal of Urology found the use of PSA density less than 0.15 ng/ml/ml in the presence of prebiopsy negative MRI was the most useful factor to identify men without clinically significant prostate cancer who could avoid biopsy.  Learn more here.

read more
Dr. Busch Speaks with Atlanta Business RadioX

Dr. Busch Speaks with Atlanta Business RadioX

Atlanta Business RadioX Interview with Dr. Joe Busch Listen as Dr. Busch talks with Lee Cantor from Atlanta Business RadioX about how the three most common methods to detect prostate cancer are fraught with problems and errors. In the U.S., medical teams typically use either prostate-specific antigen (PSA) blood tests, blind needle biopsies, or digital rectal exams to determine whether a man has prostate cancer. Dr. Busch says these methods are...

read more
Busch Center Uses the Safest, Most Stable Contrast Dye and Only When Necessary

Busch Center Uses the Safest, Most Stable Contrast Dye and Only When Necessary

At Busch Center, many of our scans and screenings are done with noneedles, contrast dye, or radiation for a more comfortable patient experience.  In some cases, however, our magnetic resonance imaging (MRI) scans require us to use contrast agents to get a more robust view to see if (and where) cancer is located in the body. In the cases where contrast dye is necessary, we opt to use Dotarem because it’s the best, safest, most stable, and...

read more
Agent Orange: Likely a Prostate Cancer Risk Factor

Agent Orange: Likely a Prostate Cancer Risk Factor

Research shows that exposure to Agent Orange, an herbicide frequently used during the Vietnam War, likely caused an aggressive form of prostate cancer in many Vietnam veterans. The U.S. military used significant amounts of Agent Orange, which was contaminated with dioxin, a dangerous toxin that is now believed to cause cancer, to spray on trees and other vegetation. Soldiers who served in Vietnam between 1962-1975 were likely exposed to this...

read more
PSA Screenings: A Good Idea at Any Age

PSA Screenings: A Good Idea at Any Age

What is PSA? The prostate makes a protein called prostate-specific antigen (PSA), which is measured by a blood test.  If the PSA is high, the patient may have prostate cancer, but other factors (including an enlarged prostate or certain medications) can also cause elevated numbers. How are PSA Screenings Helpful? Prostate cancer is the most common form of cancer in men, besides skin cancer.  Research shows that 1 in 9 men will be...

read more
Transurethral Ultrasound Ablation (TULSA) for Prostate Cancer Treatment: An Interview With Joseph J. Busch, Jr., MD

Transurethral Ultrasound Ablation (TULSA) for Prostate Cancer Treatment: An Interview With Joseph J. Busch, Jr., MD

Dr Busch was recently interviewed by IO Learning about integrating the recently FDA-approved TULSA treatment into his practice. He explained that in the phase 2 trial ... "They treated the entire gland with TULSA, and compared it with prostatectomy, with 4-year data now available. First, they’ve shown that they can kill cancer with this technique. Second, and very importantly, they’ve shown that 90% of the men who had sexual function before the...

read more
Incision-Free, Radiation-Free Prostate Cancer Treatment Now Available in Georgia

Incision-Free, Radiation-Free Prostate Cancer Treatment Now Available in Georgia

ALPHARETTA, GA. (PRWEB) MARCH 25, 2020 Busch Center First in State to Offer Groundbreaking TULSA Procedure Busch Center, the leading prostate MRI facility in America, is now offering a groundbreaking cancer treatment procedure, known as the TULSA (Transurethral Ultrasound Ablation) Procedure, which requires no incision, no radiation and is customized to treat only unhealthy prostate tissue. Busch Center is one of the few elite facilities...

read more

Medical Studies

Personalized Treatment for Patients with Prostate Cancer Using MRI-guided Transurethral Ultrasound Ablation (TULSA)

MAGNETOM Flash
TULSA is a new technology which has demonstrated promising early oncological results with a well-tolerated safety profile. As Prostate Cancer disease localization continues to improve, it is expected that targeted treatment will become increasingly part of localized Prostate Cancer management. As MRI is already embedded within TULSA, used both to guide, plan, and monitor treatment, TULSA is well-positioned to address the changing landscape of Prostate Cancer disease management.

Palliative MRI-guided Transurethral Ultrasound Ablation for Symptomatic Locally Advanced Prostate Cancer

Scandinavian Journal of Urology
The study concludes TULSA appears safe and feasible for palliative ablation of locally advanced prostate cancer. The therapy seems to accomplish long-term hematuria control, can relieve bladder outlet obstruction in selected patients, and seems to reduce the burden of hospitalization due to local complications.

MRI-Guided Transurethral Ultrasound Ablation for BPH

Journal of Endourology
This retrospective analysis demonstrates promising safety and feasibility of TULSA to relieve LUTS, with improvements in IPSS comparable to modern minimally invasive surgical therapies. Larger controlled studies with BPH-specific ablation plans in men seeking treatment for LUTS are warranted.

Patient Testimonials

Elevated PSA Levels

Busch Center Experience

America’s Flawed Standard of Care

Importance of Early Detection Through Screening

About Prostate MRI Screening

Treating Prostate Cancer

TULSA Procedure